| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441089 | European Journal of Cancer | 2016 | 8 Pages |
Abstract
Sunitinib rechallenge is a feasible treatment option with potential clinical benefit for mRCC patients. Disease progression with first-line sunitinib may not be associated with complete or irreversible resistance to therapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Stéphane Oudard, Lionnel Geoffrois, Aline Guillot, Christine Chevreau, Jean-Laurent Deville, Sabrina Falkowski, Helen Boyle, Marjorie Baciuchka, Pierre Gimel, Brigitte Laguerre, Mathieu Laramas, Christian Pfister, Delphine Topart, Frédéric Rolland,